Latest News
FOR IMMEDIATE RELEASE
American Pathology Partners launches new molecular diagnostics division based in Denver, Colorado 
September 27, 2010 - Brentwood, Tennessee
American Pathology Partners (APP) announced today that it has launched its new molecular diagnostics division effective September 1, 2010. The division, based in Denver, Colorado, is headed by Deborah Payne, Ph.D., Vice President of Molecular Services.
“We launched this division almost one year after Dr. Payne joined us to lead the effort, and we are very pleased with the results” commented Robert Mignatti, chief operating officer of American Pathology Partners. Mr. Mignatti added “the first wave of offered tests complements and supports our very active women’s health program but we expect to also introduce in the near future additional molecular tests in the oncology area.” Thanasis Papaioanu, chief development officer, added “during the past year, Dr. Payne’s team internally developed and validated 12 molecular tests on both the SurePath™ and ThinPrep® liquid cytology vials in addition to HPV, Chlamydia and Gonorrhea, allowing us to further elevate our already industry-leading women’s health offering.”
Prior to joining American Pathology Partners, Dr. Payne was Director of the Molecular Diagnostic Laboratory of the University of Texas Southwestern Medical Center in Dallas, Texas where she was also Associate Professor of Pathology. Dr. Payne, who received her Ph.D. in Microbiology and Immunology from the University of Texas Medical Branch in Galveston, Texas, is internationally recognized in molecular diagnostics. She is an active speaker and well published having authored or co-authored several book chapters and 55 manuscripts; she is also on the editorial board for LabMedicine. Dr. Payne is also an active member of numerous committees and industry organizations, including serving as co-chair for the NACB Laboratory Practice Guidelines Committee on Pharmacogenetics; serving as the only U.S. member on the Committee for Molecular Diagnostics for the International Federation for Clinical Chemistry (IFCC); and serving as a member of the Board of Directors for the American Board of Clinical Chemistry (ABCC). Dr. Payne previously also served as a voting member on the Molecular and Clinical Genetics Devices Panel of the Medical Devices Advisory Committee of the FDA.
Edward Dooling, chief growth officer, commented “the molecular lab expansion allows APP to provide a more integrated and comprehensive women’s health offering across the organization, and make it available to all of our partner laboratories.”
Contact:
Thanasis Papaioanu, Chief Development Officer
(615) 815.5088
thanasis@ap2.com
| Back to Top |